Background: Novel targeted agents have been increasingly developed and tested in clinical trials over the past\n5ââ?¬â??10 years, many with unknown and unanticipated side effects. We describe here a case of a patient with a history\nof metastatic follicular thyroid carcinoma that we believe developed vandetanibââ?¬â??associated photoallergic dermatitis\nwhile enrolled on a phase 1 clinical trial.\nCase presentation: A 51-year-old Caucasian female with poorly differentiated, metastatic follicular thyroid carcinoma\npresented with a cutaneous eruption that developed over 3 to 4 days while treated on phase 1 clinical trial with\nvandetanib-based therapy. Given the concern for photoallergic dermatitis, vandetanib was discontinued and\nsupportive care provided including topical and oral steroid administration. Her cutaneous eruption improved and\nshe was successfully re-challenged with vandetanib.\nConclusion: Tyrosine kinase inhibitors, such as typo-vandetinib, with various therapeutic targets have come to the\nforefront of oncologic therapy in recent years. It is important to have a better understanding of the side effect\nprofile and management in order to anticipate adverse events and maintain patient safety in future clinical trials
Loading....